Sector News

Bayer sets up triumvirate of managers to run slimmed-down operation

September 21, 2015
Life sciences

Change is coming for Bayer–and with it, change at the top. The German pharma has outlined its plans for retooling, post-plastics division divestment–and they involve three operational arms, each headed up by a company vet.

Once the company’s MaterialScience unit becomes new company Covestro, Bayer will reorganize into three new divisions: Pharmaceuticals, under the direction of Dieter Weinand; Consumer Health, to be led by Erica Mann; and Crop Science, which Liam Condon will head. All three will take a seat on Bayer’s management board on Jan. 1 of next year, Bayer said.

“We are convinced that the greater integration of strategic and operational roles will take Bayer forward, and we have expanded the roles of the board of management members accordingly,” Chairman Werner Wenning said in a Friday statement.

It’s all part of the drugmaker’s ambitions to become a more life-sciences-focused company once plastics are out of the picture. According to CEO Marijn Dekkers, the new structure will provide the “best possible support” for the new life-sciences-centric strategy and help the company better compete against its rivals in the field.

It’ll be embarking on that path beginning in the fourth quarter, Bayer said recently; that’s when it plans to float the new Covestro shares, with an eye on raising about €2.5 billion ($2.84 billion). It’ll be offering between 70.4 million and 94.2 million new shares from a capital increase at an issue price of between €26.50 and €35.50 apiece, Reuters reports.

Also joining Bayer’s board to start the new year will be Hartmut Klusik, who will take up the reins as the member responsible for HR, tech and sustainability. He’ll step in for Michael König, who has requested his contract not be extended.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend